What do systematic reviews say?

Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone

• Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 500 participants
  Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone

• Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 224 participants
  Very low

Antihistamines vs scopolamine

• Antihistamines for motion sickness 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Very low

28 days on/off antibiotic regimen vs 28 days on/off placebo regimen

28 days on/off antibiotic regimen showed no clear difference in hospitalisation for pulmonary exacerbations compared with 28 days on/off placebo regimen (high certainty).

• Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
  OR 0.79 [0.49, 1.29]
  Studies not reported
  High

14 days on/off antibiotic regimen vs 28 days on/off antibiotic regimen

The review found no eligible studies for this question.

• Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

14 days on/off antibiotic regimen vs 14 days on/off placebo regimen

The review found no eligible studies for this question.

• Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs ACBT

• Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Exercise vs underwater PEP (uPEP; also known

The review found no eligible studies for this question.

• Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise plus PD&P vs PD&P only

• Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 55 participants
  Very low

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival: overall population compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.39 [0.32, 0.46]
  5 studies · 1263 participants
  High

Pregabalin 300 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ambulation vs non‐ambulation

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 130 participants
  Very low

Summary of findings table ‐ Ibuprofen 800 mg vs prophylactic ibuprofen 800 mg women having medical abortion before 14 weeks? gestation

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 1600 mg vs paracetamol

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anticoagulant vs no treatment

It is very uncertain whether anticoagulants changes pulmonary embolism compared with no treatment (very low certainty).

• Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
  RR 24.19 [3.31, 176.53]
  1 study · 1403 participants
  Very low

Higher‐dose anticoagulants vs lower‐dose anticoagulants

Higher‐dose anticoagulants probably leads to lower pulmonary embolism compared with lower‐dose anticoagulants (moderate certainty).

• Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
  RR 0.46 [0.31, 0.7]
  4 studies · 4360 participants
  Moderate

Mask vs prongs

It is very uncertain whether mask changes bronchopulmonary dysplasia compared with prongs (very low certainty).

• Masks versus prongs as interfaces for nasal continuous positive airway pressure in preterm infants 2022 · Cochrane Headline outcomes only
  RR 0.69 [0.46, 1.03]
  7 studies · 843 participants
  Very low

Anticoagulant vs control

Summary of findings table ‐ Anticoagulant leads to lower symptomatic pulmonary embolism during treatment period compared with control (high certainty).

• Anticoagulants for acute ischaemic stroke 2021 · Cochrane Headline outcomes only
  OR 0.6 [0.44, 0.81]
  14 studies · 22544 participants
  High

Dornase alfa vs alternate days

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  43 participants
  Low